PRAS40 mediated mTORC1 inhibition prevents the development of cardiomyopathy, along with improved metabolic function, insulin sensitivity, and reduced systemic hyperglycemia in a diabetic mouse model [42]. Here, INS is linked to Hyperglycemia.